Key result
Bortezomib for multiple myeloma is linked to heart failure and midwall myocardial fibrosis on CMR.
Why the study?
Myocardial scarring following chemotherapy for multiple myeloma and its detection by cardiovascular magnetic resonance is not well characterized.
Answers are grounded in this paper and cite their sources.
Late gadolinium enhancement cardiovascular magnetic resonance can detect midwall fibrosis in patients developing heart failure after bortezomib chemotherapy.
We present the case of a 60-year-old lady who was treated with chemotherapy for myeloma. Following initiation of bortezomib, she developed heart failure which was associated with a reduction in left ventricular systolic function. A gadolinium enhanced cardiovascular magnetic resonance scan demonstrated midwall hyperenhancement consistent with midwall fibrosis.
No takes yet. Share an insight, caveat, or question.
Foley et al. (2010) studied this question. Bortezomib chemotherapy for multiple myeloma was associated with heart failure and midwall myocardial fibrosis detected by gadolinium-enhanced cardiovascular magnetic resonance.
Synapse has enriched 10 related papers. Consider them for comparative context: